LogicBio Therapeutics Inc

-0.02 (-5.11%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)9.00M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$2 Million
Adjusted EPS-$0.21
See more estimates
10-Day MA$0.34
50-Day MA$0.41
200-Day MA$0.84
See more pivots

LogicBio Therapeutics Inc Stock, NASDAQ:LOGC

65 Hayden Avenue, 2nd floor, Lexington, Massachusetts 02421
United States of America
Phone: +1.617.245.0399
Number of Employees: 62


LogicBio Therapeutics, Inc. engages in the development of a genome editing technology platform. It focuses on the commercialization of GeneRide, which enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination. Its pipeline includes LB-001, LB-301 and LB-401. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Lexington, MA.